You are here

For the media

Contact Caroline Marin at 612-624-5680 to request an interview with an expert from any one of our health sciences programs. She will work with our entire public relations team to ensure your request is handled immediately.

UMN study shows regulation is needed for cancer causing chemicals in smokeless tobacco products

Thursday, December 18, 2014

New research from the University of Minnesota shows the level of cancer causing chemicals in smokeless tobacco products varies widely, and these levels play an important role in the extent of the body’s exposure to these chemicals even when taking into account how the product is used. The results indicate a need for FDA-mandated standards on smokeless tobacco products to protect public health.

The study is published in the latest issue of Cancer Prevention Research, a journal of the American Association for Cancer Research.

UMN mourns loss of Lee Wattenberg, M.D., recognized as the “father of chemoprevention”

Thursday, December 11, 2014

The faculty and staff of the University of Minnesota and the Masonic Cancer Center, University of Minnesota are mourning the loss of cancer pioneer Lee Wattenberg, M.D. Wattenberg died December 9 at the age of 92, and will be remembered for his immense contribution to the field of chemoprevention.

Wattenberg is credited with the creation of an entire field of research in the wake of his landmark 1966 paper in Cancer Research examining the effects of certain compounds on cancer development.  This led to a new emphasis on understanding cancer prevention, including the use of foods such as cabbage and broccoli to try to prevent cancer.

Study Suggests Unique Way to Prevent Infection after Kidney Transplant

Wednesday, December 10, 2014

Viral infections are a leading cause of disease and death in patients receiving a kidney transplant. But a recent University of Minnesota study suggests a unique way to prevent the transmission of common viruses during kidney transplants.

Published in the journal Transplantation, the study tested whether inhibiting two common viruses in donors by giving them an antiviral drug would reduce the amount of virus transmitted by the donor kidney at transplantation.

University of Minnesota to offer new retinal prosthesis device in clinical trial

Monday, December 1, 2014

New visual prosthetic gives sight to patients with retinitis pigmentosa

A new device designed to restore some sight in patients blind due to retinitis pigmentosa is now being offered at the University of Minnesota. Designed by Second Sight Medical Products, ArgusII is the world’s first FDA approved artificial retina.

Known as a “retinal prosthesis system,” the Argus II is designed to partially restore vision in people with retinitis pigmentosa, a rare genetic condition severely damaging photoreceptors in the eye, causing blindness.